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Abstract
Skull-base osteomyelitis (SBO) occurs secondary to invasive bacterial and fungal infection. Distinguishing between fungal and bacterial
aetiologies of SBO has signiﬁcant therapeutic implications. An 18-year (1990–2007) retrospective review of patients with SBO present-
ing to Westmead Hospital was performed. Epidemiological, clinical, laboratory and radiology data were collated. Twenty-one patients
(median age 58 years) with SBO were identiﬁed: ten (48%) had bacterial and 11 (52%) had fungal SBO. Diabetes mellitus (57%) and
chronic otitis externa (33%) were the most frequent co-morbidities; immunosuppression was present in ﬁve cases (24%). Cranial nerve
deﬁcits occurred in ten (48%) patients. The commonest pathogens were Pseudomonas aeruginosa (50% bacterial SBO) and a zygomycete
(55% fungal SBO). Compared to bacterial SBO, fungal SBO was more frequently associated with underlying chronic sinusitis, sinonasal
pain, facial/periorbital swelling and nasal stufﬁness or discharge and the absence of purulent ear discharge (all p <0.05). Bacterial SBO
was more frequently associated with deafness, ear pain or ear discharge (all p <0.05). Median time to presentation was longer in
patients with bacterial SBO (26.3 weeks vs. 8.1 weeks, p 0.08). Overall 6-month survival was 88% (14/18 patients). All four deaths
occurred in patients with fungal SBO. Immunosuppression was a risk factor for death (p <0.05). Early diagnostic sampling is recom-
mended in patients at increased risk of fungal SBO to enable optimal antimicrobial and surgical management.
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First described in 1959 by Meltzer and Kelemen [1],
skull-base osteomyelitis (SBO) is an uncommon condition
associated with signiﬁcant morbidity and mortality [2–4].
Subsequently, our understanding of SBO is derived from case
reports or small series in the surgical literature [1–15]. The
entity has been described most often as a complication of
malignant otitis externa secondary to Pseudomonas aeruginosa
infection [5,16]. Increasing age, diabetes mellitus and micro-
vascular disease are common risk factors [2,9].
SBO, however, may also occur in the absence of
malignant otitis externa and with pathogens other than
P. aeruginosa, including fungi [3,7,8,12–14,17]. Fungal SBO
has been reported to be mostly caused by Aspergillus, and
less commonly, Scedosporium spp. [3,7,12]. Although under-
lying diabetes and primary or acquired immunodeﬁciencies
have often been evident [12], fungal SBO has also occurred
in the absence of these traditional risk factors [10,12,15].
Early diagnosis, identiﬁcation of the causative pathogen(s),
prompt initiation of appropriate antimicrobial or surgical
therapies, and continuation of therapy for an adequate per-
iod are essential when managing SBO. Identiﬁcation of the
pathogen often requires surgical biopsy. Because this may be
delayed for medical or technical reasons, clinical features or
risk factors that discriminate between SBO caused by bacte-
ria and that due to fungi could guide selection of empiric
antimicrobial therapy pending deﬁnitive diagnosis. Using data
from cases at a single institution over 18 years, we com-
pared the epidemiology and clinical characteristics of bacte-
rial and fungal SBO, aiming to identify unique risk factors and
clinical associations.
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Materials and Methods
Study design
A retrospective study of SBO was undertaken at a university
hospital over 18 years (1990–2007). Cases were identiﬁed
following interrogation of medical records using the Interna-
tional Statistical Classiﬁcation of Diseases and related Health
Problems deﬁnitions, 10th revision, Australian modiﬁcation
[18]. Key words included: ‘base of skull’, ‘osteomyelitis’,
‘malignant otitis externa’, ‘otitis media’, ‘sinusitis’, ‘diseases of
the petrous temporal bone’ and ‘invasive mycoses’. The
Microbiology, Otorhinolaryngology and Histopathology data-
bases were also queried for cases of SBO. Approval for the
study was obtained from Sydney West Area Health Service
Human Research Ethics Committee.
For each patient, clinical information was recorded on a
standardized form and included: patient demographics, co-
morbidities and predisposing factors within the preceding
90 days, likely source of infection (ear, sinus, other), clinical
features, results of microbiological and histopathological
investigations, treatment, hospital length of stay and clinical
outcome at 6 months. Results of computed tomography
(CT), magnetic resonance imaging (MRI) or combined tech-
netium Technitium-99m/gallium citrate (Ga)]-67 scans were
assessed by one author (LG), who was blinded to the other
results.
Deﬁnitions
Proven (deﬁnite) SBO was deﬁned as skull-base infection in
patients with localizing symptoms/signs at presentation who
had: (i) radiological or scintigraphic features indicative of bone
erosion and/or infection and (ii) isolation and/or visualization
of the pathogen from the affected bone(s) and surrounding
tissue. Probable SBO was deﬁned as infection in patients with
localizing symptoms/signs with evidence of SBO on imaging
studies, but from whom a pathogen was recovered from
clinical specimens other than bone or tissue (e.g. ear swabs)
or in whom a deﬁnite response to antimicrobial therapy was
evident. The primary source of the pathogen was assigned
according to patient clinical features in the context of accom-
panying microbiological and radiological results.
Statistical analysis
Clinical data were analyzed using SPSS, version 15.0.0 (SPSS
Inc., Chicago, IL USA). Variables associated with SBO caused
by bacteria were compared with those associated with fungal
SBO. Analyses were also performed to examine risk factors,
presenting symptoms, causative pathogen, and treatments
administered associated with survival at 6 months. Univariate
analyses were performed using a Student’s t-test (for contin-
uous variables) or the chi-square or Fisher’s exact tests (for
categorical variables); p <0.05 was considered statistically
signiﬁcant.
Results
Demography and predisposing factors
From over 500 patients identiﬁed through the search, 21
patients met the case deﬁnition of SBO; 15 had proven SBO
and six had probable infection. The mean patient age was
58 years (range 26–80 years); 66.7% were male.
Diabetes mellitus was the most frequent predisposing fac-
tor (12 patients; 57%) followed by chronic otitis externa
(33%) and underlying chronic sinusitis (29%; Table 1). Of ﬁve
immunosuppressed patients, three had rheumatoid arthritis
and were receiving corticosteroids alone, methotrexate
alone, or corticosteroids, methotrexate and adalimumab
TABLE 1. Demographics, risk factors, clinical features, site
of original disease and outcome in 21 patients with skull-
base osteomyelitis (SBO)
Bacterial
SBO (n = 10)
Fungal
SBOa (n = 11) Signiﬁcance
Predisposing factors
Mean age, years (range) 56 (26–80) 56 (32–72) NS
Diabetes 4 (40.0%) 8 (72.7%) NS
Chronic otitis media 4 (40.0%) 2 (18.2%) NS
Chronic otitis externa 5 (50.0%) 2 (18.2%) NS
Chronic sinusitis 0 6 (54.5%) p <0.02
Immunosuppression 1 (10.0%) b4 (36.4%) NS
Trauma or surgery 3 (30.0%) 1 (9.1%) NS
Mean time to presentation
weeks (95% CI)
26.3 (4.2–28.5) 8.1 (0.6–15.5) NS (p 0.08)
Clinical features
Fever 3 (30.0%) 6 (54.5%) NS
Headache 4 (40.0%) 8 (72.7%) NS
Deafness 7 (70.0%) 2 (18.2%) p 0.03
Ear pain 8 (80.0%) 2 (18.2%) p <0.009
Ear discharge 8 (80.0%) 1 (9.1%) p <0.002
Sinonasal pain 1 (10.0%) 8 (72.7%) p <0.008
Facial or periorbital swelling 1 (10.0%) 7 (63.6%) p 0.024
Nasal stufﬁness or discharge 3 (30.0%) 9 (81.8%) p 0.03
Cranial nerve involvement 5 (50.0%) 5 (45.5%) NS
Eye/orbit infection 0 2 (18%) –
Brain parenchymal infection 0 1 (9%) –
Site of original infection
Ear disease 8 (80.0%) 2 (18.2%) p <0.01
Sinus disease 0 9 (81.8%) p <0.001
Traumatic or uncertain 2 (20.0%) 0 NS
Therapy received
Surgery 5 (50.0%) 11 (100%) p <0.02
Antibacterial Therapy 10 (100%) 6 (54.5%) p <0.04
Antifungal therapy 0 11 (100%) p <0.001
Hyperbaric oxygen Therapy 0 2 (18.2%) NS
Outcome
Survival (6 months) 7/7 (100%) 7/11 (63.6%) NS (p 0.12)
Disease-free survival
(6 months)
5/7 (71.4%) 7/11 (63.6%) NS
SBO, Skull-base osteomyelitis; NS, not signiﬁcant.
aInclusive of one patient with mixed fungal and bacterial osteomyelitis.
bOne patients with rheumatoid arthritis receiving immunosuppressive therapy
had mixed bacterial and fungal infection. Both patients post transplantation (hae-
matopoietic stem cell and renal transplantation) had fungal infection.
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(each n = 1); one renal transplant patient was receiving
cyclosporine and azathioprine, and a haematopoietic stem
cell transplant recipient was receiving corticosteroids.
Clinical features and site of bone infection
The median time from symptom onset to SBO diagnosis was
7 weeks (range 1 week–2 years).The most frequent clinical
features are summarized in Table 1. Cranial nerve palsies
were present in ten (48%) patients affecting the facial (n = 7
patients), ophthalmic (n = 7), optic (n = 4), ophthalmic,
trochlear or abducens (each n = 4), and glossopharyngeal
(n = 4), nerves. Infection extending into the orbit/eye and
brain was uncommon (Table 1).
All patients had radiographic or scintigraphic evidence of
SBO (CT, n = 17; MRI, n = 11; Tm-99/Ga-67 scintigraphy,
n = 16). Three patients had evidence of bilateral disease
(14%). The petrous temporal bone was most frequently
involved (13/21, 62% cases; Fig. 1) followed by the maxillary
sinus wall (7/21; 33%), sphenoid or clivus (5/21; 24%), nasal
bones (5/21; 24%), ethmoid or sphenoid sinus wall (4/21;
19%) and squamous temporal bone (2/21; 10%).
The likely source of infection was determined in 20 patients
(95%); ten were considered to have had a primary ear infec-
tion (including mastoiditis), and nine had primary sinus infec-
tion. One patient developed infection post trauma (Table 2).
Microbiological and histopathological ﬁndings
Clinical specimens (e.g. sinus material, pus from ear) were
obtained for culture from all patients, including 15 patients
who underwent surgical biopsy. Biopsy specimens (bone, 15/
15; sinus tissue, 7/15; periorbital tissue, 1/15; ear tissue, 1/
15) all demonstrated tissue necrosis with or without visible
microorganisms.
Overall, a bacterial pathogen was cultured from seven
patients, and a fungal pathogen was cultured, or visualized,
in 11 cases (Table 2). Of six patients with probable bacte-
rial SBO, two had P. aeruginosa cultured from purulent ear
material, whereas Gram-negative rods were seen in the ear
ﬂuid of another. A single patient had mixed bacterial and
fungal SBO (Table 2) and was included in the ‘fungal SBO’
group for analyses (see below). Thus, there were ten
patients with bacterial SOB and 11 with fungal infection
(Table 1).
P. aeruginosa was the most frequent bacterial pathogen (5/
10 cases of bacterial SBO, one case of mixed infection;
Table 2). Zygomycetes were the most common fungal patho-
gen (n = 6); in three patients, broad pauci-septate hyphae
were seen in bone but no fungus was cultured. There were
two cases each due to Scedosporium apiospermum and Asper-
gillus spp. Of six patients who had blood cultures, one
yielded Acinetobacter spp.; the organism was also cultured in
this case from pus/tissue from the external ear.
Comparison of bacterial and fungal SBO
Predisposing factors for bacterial and fungal SBO were simi-
lar, although a greater proportion of patients with fungal
SBO had underlying chronic sinusitis (55% vs. 0%; p <0.02)
(Table 1). Thirty-six percent of fungal SBO patients were
immunosuppressed compared to 10% of those with bacterial
SBO (p: not signiﬁcant).
There was a trend towards more rapid presentation with
fungal SBO (mean time to presentation 8 weeks vs.
26 weeks for bacterial SBO; p 0.08; Table 1). Other differ-
ences in presenting symptoms/signs were also observed
between the two patient groups: deafness and ear pain or
purulent discharge were associated with bacterial SBO
(p £0.03), whereas sinonasal pain, facial or periorbital swell-
ing and nasal stufﬁness/discharge were more frequent in fun-
gal SBO (p £0.03). No signiﬁcant differences in the frequency
or magnitude of fever, or in the proportion of cranial nerve
deﬁcits, were identiﬁed (Table 1).
Overall, bacterial SBO was more likely than fungal SBO to
have arisen from an otogenic focus of infection (80% vs.
18.2%; p <0.01). Conversely, fungal SBO was more likely to
have originated from the sinuses (82% vs. 0%; p <0.001;
Table 1). Absence of ear discharge was the most sensitive
predictor of fungal SBO, with a sensitivity of 91% and speci-
ﬁcity of 80%, whereas the presence of sinonasal pain yielded
a sensitivity of 73% and speciﬁcity of 90% for fungal SBO.
FIG. 1. Axial computed tomography (bone windows) demonstrating
typical appearances of skull-base osteomyelitis of the right petrous
temporal bone with erosion (arrow) into the right foramen ovale
and foramen lacerum.
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Treatment and outcomes
Surgical debridement (n = 16) was performed more fre-
quently with fungal SBO (100% vs. 50%, p <0.02). Antibacte-
rial therapy was administered to all patients with bacterial
SBO and six with fungal SBO prior to diagnosis. The median
length of antibacterial therapy was 12 weeks [bacterial SBO,
13 weeks (range 4–26 weeks); fungal SBO, 5 weeks (range
1–18 weeks)]. Fifteen patients received an anti-pseudomonal
b-lactam antibiotic (ticarcillin/clavulanic acid (n = 10) or ceft-
azidime (n = 5), 11/16 ciproﬂoxacin and 5/16, vancomycin.
All patients with fungal SBO received antifungal therapy [lipid
amphotericin B formulation (7/11), itraconazole (2/11), voric-
onazole (3/11), posaconazole (4/11) and caspofungin (1/11)].
The median duration of therapy was 28 weeks. The median
length of hospital stay for 19 patients was 3 weeks (bacterial
SBO, 2.6 weeks; fungal SBO, 5 weeks; p: not signiﬁcant).
Six-month survival was 77% (14/18 patients); three
patients with bacterial SBO were lost to follow-up. Four
deaths occurred, all in patients with fungal SBO (median time
from diagnosis to death: 8 weeks; range 2–18 weeks). The
cause of death in all cases was progressive fungal disease;
secondary haemorrhage from mycotic aneurysms [internal
carotid artery (n = 1), superior cerebellar artery (n = 1)]
was contributory in two cases. Cranial nerve abnormalities
persisted in all patients. The median time from symptom
onset to initiation of therapy was 5 weeks (range 1–13
weeks) in those who died compared to 11 weeks in survi-
vors (range 2–53 weeks; p: NS). Immunosuppression was the
only factor associated with decreased survival by univariate
analysis (40% vs. 92% in non-immunosuppressed patients,
p <0.05). Fungal SBO per se was not associated with
decreased survival (Table 1).
Discussion
SBO, usually a complication of uncontrolled otogenic, odon-
togenic or sinus infection, is uncommon [3,11,14]. Large,
adequately powered epidemiological studies have not been
published. The prevalence of SBO and the relative contribu-
tion of bacteria and fungi are difﬁcult to estimate from previ-
ous case series as a result of small patient numbers, the
frequent inclusion of patients with malignant otitis externa
without conﬁrmed SBO and variation in the diagnostic meth-
ods used [6,9,16]. The present study, using strict case deﬁni-
tions for SBO, reveals that fungi accounted for a signiﬁcant
proportion (approximately 50%) of SBO in contemporary
hospital practice. We have also identiﬁed clinical variables
associated with fungal, or bacterial, SBO that may guide initi-
ation of early diagnostic sampling and/or selection of empiric
antimicrobial therapy.
The signiﬁcant morbidity of SBO in the present study is
consistent with previous reports [3,4,6]. Almost half (48%)
of patients had persistent cranial nerve abnormalities, compa-
rable to that reported elsewhere (21–43%) [3,6,19].
Although extension into brain was uncommon [6, present
study], cerebral involvement has been associated with high
mortality in reported cases despite surgical intervention; the
single patient in our series succumbed to fungal infection
before surgery could be considered. A large proportion of
patients suffered disﬁguring surgery with an attendant pro-
longed hospital stay (median 3 weeks). As noted in other
studies [3,6,16], diabetes mellitus and chronic ear disease
were predisposing factors. However, conﬁrmation of under-
lying chronic sinusitis as a risk factor for SBO is required.
TABLE 2. Microbiology and site of infection
Site of disease
Bacterial SBO (n = 10) Fungal SBO (n = 11)
Proven bacterial (n = 4) aProbable bacterial (n = 6) Fungal (n = 10)
Mixed bacterial and
fungal (n = 1)
Ear Pseudomonas aeruginosa and
Staphylococcus aureus (n = 1)
P. aeruginosa (n = 1)
bAcinetobacter spp. (n = 1)
c5 Scedosporium apiospermum (n = 2)
Sinus – – Aspergillus fumigatus (n = 1)
Aspergillus ﬂavus (n = 1)
Rhizopus spp. (n = 2)
Mucor spp. (n = 1)
dZygomycete (n = 2)
Dematiaceous fungus (n = 1)
P. aeruginosa,
S. aureus and
dZygomycete (n = 1)
Traumatic inoculation P. aeruginosa (n = 1) – – –
Uncertain – 1 – –
aAs determined by isolation of organism from specimens other than bone/tissue and/or clinical improvement on antibacterial therapy.
bAcinetobacter spp. isolated from blood and pus/tissue from the external ear.
cTwo had P. aeruginosa detected in pure culture of samples taken from the external auditory meatus, and one had Gram-negative rods visualized in pus from the external
ear.
dIdentiﬁed by histological assessment only.
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Otogenic P. aeruginosa infection accounted for 50% of
bacterial SBO. This is consistent with the adage that SBO
complicating malignant otitis externa is almost uniformly
caused by this bacterium [16,20]. However, other bacteria,
and fungi are also important causes of SBO [3,6]. Fungal
SBO is increasingly reported in the literature
[3,7,10,12,15,17,21], although no systematic long-term epide-
miological studies have been conducted. This apparent rise
may reﬂect the increasing use of immunosuppressive thera-
pies, in parallel with the rise of other forms of invasive fun-
gal disease (IFD) [21,22]. Indeed, four of ﬁve
immunosuppressed patients in our study had fungal SBO
(Table 1). Importantly, however, fungal SBO may also occur
in immunocompetent individuals [10,15, present study] and
should be considered in all patients presenting with symp-
toms/signs of SBO, especially given evidence from other
forms of IFD that delay in antifungal therapy results in
increased mortality [23,24].
Most cases of fungal SBO have been due to Aspergillus
or Scedosporium spp., reportedly arising from contiguous
spread of ear infection [7,10,12,17], although one report
noted fungi to be a rare cause of invasive otitis externa
[25]. In comparison, we observed that fungal SBO
occurred primarily as a result of antecedent sinus infection
and that zygomycetes were the most frequent pathogen.
The reasons for the relative prevalence of zygomycetes
are not readily apparent but are of interest. Zygomycetes
are well-known pathogens of invasive fungal sinusitis
[3,17,21] and, as such, may have inﬂuenced the aetiology
of SBO. Although not statistically signiﬁcant, the majority
(>70%) of fungal SBO patients had diabetes, which is a
risk factor for zygomycosis [21]. By using strict case
deﬁnitions to determine SBO, we also excluded instances
of ‘colonization’, typically with fungi (e.g. Aspergillus spp.)
other than zygomycetes. It is possible that local
institutional epidemiology may have inﬂuenced the preva-
lence of speciﬁc fungi, although there are no data to sup-
port this.
Fungal SBO is often considered only following failure of
antibacterial therapy [7]. Kountakis et al. [7] noted that only
one of ten patients with Aspergillus SBO had received antifun-
gal therapy prior to surgical biopsy. In our study, 55% of
patients with fungal SBO were treated with antibacterial
drugs for a median of 5 weeks prior to diagnosis. It remains
uncertain how long one should wait prior to performing
diagnostic sampling.
Previous data attempting to identify risk factors for the
development of SBO have not distinguished between disease
caused by different microorganisms. Although the number of
cases included in the analysis is small and therefore the
results need to be interpreted with caution, our analyses
suggest that there may be differences in clinical risk factors
and associations for bacterial and fungal SBO. Patients with
fungal SBO were more likely to have underlying chronic
sinus disease, symptoms attributable to invasive sinus infec-
tion (sinofacial pain, periorbital swelling, nasal stufﬁness/dis-
charge), but with a relative paucity of features attributable to
ear infection. Indeed, the absence of purulent ear discharge
was a sensitive (91%) predictor of underlying fungal SBO
(Table 1). These associations warrant further investigation
through larger prospective multi-centred epidemiological
studies. Nonetheless, the results may assist in identifying
patients most likely to beneﬁt from early antifungal therapy.
Given the diversity of fungal pathogens identiﬁed, diagnostic
sampling should be performed, where possible, prior to com-
mencing therapy. However, because no clinical association
was 100% sensitive or speciﬁc for presence of fungal SBO,
clinical failure with antibacterial therapy should also prompt
similar considerations.
Antimicrobial therapy in SBO is targeted to eradication
of the causative pathogen. Because P. aeruginosa infection
predominates in most case series of bacterial SBO, inclu-
ding the present study, initiation of antibiotics with activity
against P. aeruginosa is appropriate pending microbiological
diagnosis. In the absence of local epidemiological data to
guide empiric antifungal therapy, agents with activity against
all major pathogens are necessary. Because zygomycetes
were responsible for more than 50% of fungal SBO in
our series, the use of regimens including high-dose ampho-
tericin B formulations is advised pending deﬁnitive diagno-
sis. The role of surgical resection is likely also inﬂuenced
by pathogen. Early surgery is associated with improved
survival in patients with zygomycosis [21]. Aggressive surgi-
cal debridement is recommended in fungal SBO [12] but
is probably unnecessary in patients with bacterial SBO
[6,20].
The limitations of this small retrospective study are rec-
ognized. The number of patients accessible was insufﬁcient
to fully examine signiﬁcant differences. Longitudinal data
were not collected beyond 180 days. The study, however,
used rigorous inclusion criteria and the frequent use of
biopsy to conﬁrm SBO and identify causative pathogens
was evident.
In conclusion, the present study highlights the importance
of pathogens other than P. aeruginosa, including fungi, as
causes of SBO. Certain clinical variables may enable recogni-
tion and differentiation of fungal from bacterial SBO, which
may assist clinicians in identifying patients who are at
increased risk of either type of infection and who may bene-
ﬁt from early diagnostic sampling.
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